高级检索
当前位置: 首页 > 详情页

Patient-Reported Outcomes in Chinese Patients with Locally Advanced or Recurrent Colorectal Cancer After Pelvic Exenteration

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Univ Elect Sci & Technol China, Dept Colorectal Surg, Sichuan Canc Ctr, Affiliated Canc Hosp,Sichuan Clin Res Ctr Canc,Sic, 55,Sect 4,South Renmin Rd, Chengdu, Peoples R China
出处:
ISSN:

关键词: Pelvic exenteration Colorectal cancer Patient-reported outcomes Quality of life FACT-C

摘要:
Background. Pelvic exenteration (PE) is often the only curative treatment option for selected locally advanced and locally recurrent colorectal cancer associated with significant morbidity. Open and laparoscopic approaches were accepted for this procedure. Objective. This study aimed to examine the Chinese patient-reported outcomes (PROs) and health-related quality of life (HRQoL) after PE. Methods. A total of 122 enrolled participants were asked to complete PROs at baseline and 1, 3, 6, 9 and 12 months after PE. PROs included seven symptoms from the National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). The HRQoL was assessed using the Functional Assessment of Cancer Therapy-Colorectal (FACT-C). Results. The overall postoperative complication rate was 41.0%. Patients experienced lower physical and functional well-being and FACT-C 1 month after surgery, then gradually recovered. The FACT-C score returned to baseline 9 months after surgery. Social and emotional well-being did not show signs of recovery until 6 months after the surgical procedure, and did not fully return to baseline until 12 months post-surgery. Symptom rates of insomnia, anxiety, discouragement, and sadness (composite score >0) did not improve significantly from baseline until 12 months after surgery. Conclusions. PE is a feasible treatment choice for locally advanced primary and recurrent colorectal cancer. Social, psychological, and emotional recovery in the Chinese population after PE tends to be slower compared with the physical condition.

语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2025]版:
大类 | 2 区 医学
小类 | 2 区 外科 3 区 肿瘤学
最新[2025]版:
大类 | 2 区 医学
小类 | 2 区 外科 3 区 肿瘤学
JCR分区:
出版当年[2024]版:
最新[2023]版:
Q1 SURGERY Q2 ONCOLOGY

影响因子: 最新[2023版] 最新五年平均 出版当年[2023版] 出版当年五年平均 出版前一年[2023版]

第一作者:
第一作者机构: [1]Univ Elect Sci & Technol China, Dept Colorectal Surg, Sichuan Canc Ctr, Affiliated Canc Hosp,Sichuan Clin Res Ctr Canc,Sic, 55,Sect 4,South Renmin Rd, Chengdu, Peoples R China
通讯作者:
推荐引用方式(GB/T 7714):
APA:
MLA:

相关文献

[1]Longitudinal patient-reported outcomes after minimally invasive McKeown esophagectomy for patients with esophageal squamous cell carcinoma [2]Assessment of preoperative health-related quality of life in patients undergoing thyroidectomy based on patient-reported outcomes [3]An analysis of health-related quality of life in children and adolescents after parotidectomy based on patient-reported outcomes [4]Patient-reported outcomes in adults with tyrosine kinase inhibitor-resistant chronic myeloid leukemia receiving olverembatinib therapy [5]Early Postoperative Patient-Reported Outcomes of Sarcopenia Versus Nonsarcopenia in Patients Undergoing Video-Assisted Thoracoscopic Surgery for Lung Cancer [6]Enhanced Recovery Protocol Versus Conventional Care in Patients Undergoing Esophagectomy for Cancer: Advantages in Clinical and Patient-Reported Outcomes [7]Efficacy, safety, and quality of life of dabrafenib plus trametinib treatment in Chinese patients with BRAF V600E mutation-positive metastatic non-small cell lung cancer [8]Symptom and Quality of Life Improvement in LUX-Lung 6: An Open-Label Phase III Study of Afatinib Versus Cisplatin/Gemcitabine in Asian Patients With EGFR Mutation-Positive Advanced Non-small-cell Lung Cancer. [9]Who is Seeking Traditional Chinese Medicine (TCM) for Cancer? Insights from a Large Cohort in a Rehabilitation Clinic [10]ASO Author Reflections: Pelvic Exenteration for Chinese Patients with Locally Advanced or Recurrent Colorectal Cancer: A Report of 122 Cases

资源点击量:57699 今日访问量:0 总访问量:4768 更新日期:2025-05-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持:重庆聚合科技有限公司 地址:成都市人民南路四段55号